Most-cited articles · 2024

The 100 most-cited articles in International Journal of Radiation Oncology*Biology*Physics, 2024

Ranked by OpenAlex citation count on 29 October 2026, out of 2,889 eligible articles International Journal of Radiation Oncology*Biology*Physics published in 2024. Ranks are frozen; this page will not change. Number one, with 91 citations: Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model.

Cohort
2,889 articles
Listed
Top 100 (3.5%)
Open access
65 of 100
Snapshot
2026-10-29

The most-cited articles from International Journal of Radiation Oncology*Biology*Physics in 2024 cluster around several themes. FLASH radiation therapy features prominently, with studies examining dose rate effects, normal tissue sparing, and mechanisms in preclinical models. Clinical trials in lung cancer, head and neck cancer, and prostate cancer also rank highly, as do technical reports on stereotactic and proton therapy. The top paper is "Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model" by Sørensen and colleagues, with 91 citations.

Readers can use this list to identify the studies that attracted the most attention in the citation record for the year. It reflects a mix of preclinical FLASH research, randomized clinical trial results, and technical or consensus reports. The ranking is based on OpenAlex citation counts among 2889 eligible articles and offers a neutral snapshot of which topics and publications drew the most subsequent references.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.1%

    Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model

    Brita Singers Sørensen, Eleni Kanouta, Christina Ankjærgaard, Line Kristensen, Jacob Johansen and 4 more

    91 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.071OpenAlex

    Show abstract

    PURPOSE: Preclinical studies have shown a preferential normal tissue sparing effect of FLASH radiation therapy with ultra-high dose rates. The aim of the present study was to use a murine model of acute skin toxicity to investigate the biologic effect of varying dose rates, time structure, and introducing pauses in the dose delivery. METHODS AND MATERIALS: The right hind limbs of nonanaesthetized mice were irradiated in the entrance plateau of a pencil beam scanning proton beam with 39.3 Gy. Experiment 1 was with varying field dose rates (0.7-80 Gy/s) without repainting, experiment 2 was with varying field dose rates (0.37-80 Gy/s) with repainting, and in experiment 3, the dose was split into 2, 3, 4, or 6 identical deliveries with 2-minute pauses. In total, 320 mice were included, with 6 to 25 mice per group. The endpoints were skin toxicity of different levels up to 25 days after irradiation. RESULTS: , which is the dose rate to induce a response in 50% of the animals, depended on the level of skin toxicity, with the higher toxicity levels displaying a FLASH effect at 0.7-2 Gy/s.…

  2. 2
    top 0.1%

    Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients

    Sue Sun Yom, J. Harris, Jimmy J. Caudell, Jessica Lyn Geiger, John N. Waldron and 15 more

    76 citationsdoi:10.1016/j.ijrobp.2024.08.014OpenAlex

  3. 3
    top 0.2%

    Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)

    Meredith Giuliani, Édith Filion, Sérgio Luis Faria, Vijayananda Kundapur, Thi Trinh Thuc Vu and 16 more

    65 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.050OpenAlex

    Show abstract

    PURPOSE: The use of stereotactic body radiation therapy for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (NCT03306680) aimed to determine the maximally tolerated dose of stereotactic body radiation therapy for ultracentral non-small cell lung carcinoma, using a time-to-event continual reassessment methodology. METHODS AND MATERIALS: Patients with T1-3N0M0 (≤6 cm) non-small cell lung carcinoma were eligible. The maximally tolerated dose was defined as the dose of radiation therapy associated with a ≤30% rate of grade (G) 3 to 5 prespecified treatment-related toxicity occurring within 2 years of treatment. The starting dose level was 60 Gy in 8 daily fractions. The dose-maximum hotspot was limited to 120% and within the planning tumor volume; tumors with endobronchial invasion were excluded. This primary analysis occurred 2 years after completion of accrual. RESULTS: Between March 2018 and April 2021, 30 patients were enrolled at 5 institutions. The median age was 73 years (range, 65-87) and 17 (57%) were…

  4. 4
    top 0.2%

    Redefining FLASH RT: the impact of mean dose rate and dose per pulse in the gastrointestinal tract

    Kevin Liu, Trey Waldrop, Edgardo A Aguilar, Nefetiti Mims, Denae W. Neill and 9 more

    62 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.009OpenAlex

  5. 5
    top 0.2%
  6. 6
    top 0.3%

    FLASH Proton Radiation Therapy Mitigates Inflammatory and Fibrotic Pathways and Preserves Cardiac Function in a Preclinical Mouse Model of Radiation-Induced Heart Disease

    Kyle Kim, Michele M. Kim, Giorgos Skoufos, Eric S. Diffenderfer, Seyyedeh Azar Oliaei Motlagh and 13 more

    55 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.01.224OpenAlex

    Show abstract

    PURPOSE: Studies during the past 9 years suggest that delivering radiation at dose rates exceeding 40 Gy/s, known as "FLASH" radiation therapy, enhances the therapeutic index of radiation therapy (RT) by decreasing normal tissue damage while maintaining tumor response compared with conventional (or standard) RT. This study demonstrates the cardioprotective benefits of FLASH proton RT (F-PRT) compared with standard (conventional) proton RT (S-PRT), as evidenced by reduced acute and chronic cardiac toxicities. METHODS AND MATERIALS: Mice were imaged using cone beam computed tomography to precisely determine the heart's apex as the beam isocenter. Irradiation was conducted using a shoot-through technique with a 5-mm diameter circular collimator. Bulk RNA-sequencing was performed on nonirradiated samples, as well as apexes treated with F-PRT or S-PRT, at 2 weeks after a single 40 Gy dose. Inflammatory responses were assessed through multiplex cytokine/chemokine microbead assay and immunofluorescence analyses. Levels of perivascular fibrosis were quantified using Masson's Trichrome and…

  7. 7
    top 0.3%

    Acute Hypoxia Does Not Alter Tumor Sensitivity to FLASH Radiation Therapy

    Ron Leavitt, Aymeric Almeida, Veljko Grilj, Pierre Montay‐Gruel, Céline Godfroid and 4 more

    51 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.02.015OpenAlex

    Show abstract

    PURPOSE: Tumor hypoxia is a major cause of treatment resistance, especially to radiation therapy at conventional dose rate (CONV), and we wanted to assess whether hypoxia does alter tumor sensitivity to FLASH. METHODS AND MATERIALS: We engrafted several tumor types (glioblastoma [GBM], head and neck cancer, and lung adenocarcinoma) subcutaneously in mice to provide a reliable and rigorous way to modulate oxygen supply via vascular clamping or carbogen breathing. We irradiated tumors using a single 20-Gy fraction at either CONV or FLASH, measured oxygen tension, monitored tumor growth, and sampled tumors for bulk RNAseq and pimonidazole analysis. Next, we inhibited glycolysis with trametinib in GBM tumors to enhance FLASH efficacy. RESULTS: Using various subcutaneous tumor models, and in contrast to CONV, FLASH retained antitumor efficacy under acute hypoxia. These findings show that in addition to normal tissue sparing, FLASH could overcome hypoxia-mediated tumor resistance. Follow-up molecular analysis using RNAseq profiling uncovered a FLASH-specific profile in human GBM that…

  8. 8
    top 0.3%

    Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation

    Michael P. Grams, Chrystian Quintero Mateus, Maryam Mashayekhi, Robert W. Mutter, Valentin Djonov and 12 more

    48 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.06.035OpenAlex

    Show abstract

    PURPOSE: Minibeam radiation therapy (MBRT) is characterized by the delivery of submillimeter-wide regions of high "peak" and low "valley" doses throughout a tumor. Preclinical studies have long shown the promise of this technique, and we report here the first clinical implementation of MBRT. METHODS AND MATERIALS: A clinical orthovoltage unit was commissioned for MBRT patient treatments using 3-, 4-, 5-, 8-, and 10-cm diameter cones. The 180 kVp output was spatially separated into minibeams using a tungsten collimator with 0.5 mm wide slits spaced 1.1 mm on center. Percentage depth dose (PDD) measurements were obtained using film dosimetry and plastic water for both peak and valley doses. PDDs were measured on the central axis for offsets of 0, 0.5, and 1 cm. The peak-to-valley ratio was calculated at each depth for all cones and offsets. To mitigate the effects of patient motion on delivered dose, patient-specific 3-dimensional-printed collimator holders were created. These conformed to the unique anatomy of each patient and affixed the tungsten collimator directly to the body. Two…

  9. 9
    top 0.4%

    Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial

    Devin D. Schellenberg, Zsolt Gabos, Adele Duimering, Brock John Debenham, Alysa M. Fairchild and 25 more

    46 citationsdoi:10.1016/j.ijrobp.2024.08.031OpenAlex

  10. 10
    top 0.4%

    NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy

    Harald Paganetti, Charles B. Simone, Walter R. Bosch, Daphne Adele Haas-Kogan, David G. Kirsch and 9 more

    45 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.2152OpenAlex

  11. 11
    top 0.4%

    The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives

    Amy J. Wisdom, Christopher Andrew Barker, Joe Yujiao Chang, Sandra Demaria, Silvia Chiara Formenti and 11 more

    38 citationsdoi:10.1016/j.ijrobp.2023.12.046OpenAlex

  12. 12
    top 0.5%

    A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)

    Mariana Poppe, Jennifer G. Le‐Rademacher, B. G. Haffty, Eric K. Hansen, Jay Agarwal and 15 more

    36 citationsdoi:10.1016/j.ijrobp.2024.07.002OpenAlex

  13. 13
    top 0.5%

    Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial

    Gerard Walls, Hitesh B. Mistry, Fabrice Barlési, Andrea Bezjak, Cecile Le Pechoux and 4 more

    35 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.02.063OpenAlex

    Show abstract

    PURPOSE: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered with conformal techniques. METHODS AND MATERIALS: CONVERT (NCT00433563) randomized patients 1:1 between OD RT (66 Gy/33 fractions/6.5 weeks) and BD RT (45 Gy/30 fractions/3 weeks), both delivered with concurrent cisplatin/etoposide. Three-dimensional conformal RT was mandatory, intensity-modulated RT was permitted, and elective nodal irradiation was not allowed. Prophylactic cranial irradiation was delivered at the discretion of treating clinicians. RT treatment planning was subject to central quality assurance. RESULTS: Five hundred forty-seven patients were recruited at 73 centers. The median follow-up for the surviving cohort (n = 164) was 81.2 months. The median survival for the OD and BD arms were 25.4 months (95% CI, 21.1-30.9) and 30.0 months (95% CI, 25.3-36.5; hazard ratio, 1.13; 95% CI, 0.92-1.38; P = .247). Performance status and tumor volume were…

  14. 15
    top 0.6%

    A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma

    Jiayi Huang, Jian Li Campian, Todd A. DeWees, Zdeněk Škrott, Martin Mistrík and 14 more

    34 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.009OpenAlex

  15. 16
    top 0.6%

    Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

    Lisa Francesca Licitra, Makoto Tahara, Kevin Joseph Harrington, M. Olivera Hurtado de Mendoza, Yi Guo and 15 more

    34 citationsdoi:10.1016/j.ijrobp.2024.01.016OpenAlex

  16. 17
    top 0.6%

    Whole Abdominal Pencil Beam Scanned Proton FLASH Increases Acute Lethality

    Brett I. Bell, Christian Velten, Michael Pennock, Minglei Kang, Kathryn E. Tanaka and 17 more

    33 citationsOpen accessdoi:10.1016/j.ijrobp.2024.09.006OpenAlex

  17. 18
    top 0.7%

    PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy

    Jan Hrbáček, Andrzej Kacperek, Jan-Willem M. Beenakker, Linda Mortimer, A. Denker and 6 more

    33 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.06.017OpenAlex

    Show abstract

    Although rare cancers, ocular tumors are a threat to vision, quality of life, and potentially life expectancy of a patient. Ocular proton therapy (OPT) is a powerful tool for successfully treating this disease. The Particle Therapy Co-Operative Ocular Group) formulated an Evidence and Expert-Based Executive Summary of Current Practices and Future Developments in OPT: comparative dosimetric and clinical analysis with the different OPT systems is essential to set up planning guidelines, implement best practices, and establish benchmarks for eye preservation, vision, and quality of life measures. Contemporary prospective trials in select subsets of patients (eg, tumors near the optic disc and/or macula) may allow for dosimetric and clinical analysis between different radiation modalities and beamline systems to evaluate differences in radiation delivery and penumbra, and resultant tumor control, normal tissue complication rates, and overall clinical cost-effectiveness. To date, the combination of multimodal imaging (fundus photography, ultrasound, etc), ophthalmologist assessment, and…

  18. 21
    top 0.8%

    Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial

    Sarah J. Derby, Mark R. Jackson, Karin Williams, Jamie Stobo, Caroline Kelly and 9 more

    33 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.01.011OpenAlex

    Show abstract

    PURPOSE: Patients with glioblastoma who are older or have poor performance status (PS) experience particularly poor clinical outcomes. At the time of study initiation, these patients were treated with short-course radiation therapy (40 Gy in 15 fractions). Olaparib is an oral inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) that is well tolerated as a single agent but exacerbates acute radiation toxicity in extracranial sites. Preclinical data predicted that PARP inhibitors would enhance radiosensitivity in glioblastoma without exacerbating adverse effects on the normal brain. METHODS AND MATERIALS: Phase 1 of the PARADIGM trial was a 3+3 dose-escalation study testing olaparib in combination with radiation therapy (40 Gy 15 fractions) in patients with newly diagnosed glioblastoma who were unsuitable for radical treatment either because they were aged 70 years or older (World Health Organization PS 0-1) or aged 18 to 69 years with PS 2. The primary outcome was the recommended phase 2 dose of olaparib. Secondary endpoints included safety and tolerability, overall…

  19. 22
    top 0.8%

    Probiotic Consortia Protect the Intestine Against Radiation Injury by Improving Intestinal Epithelial Homeostasis

    Liwei Xie, Haiyan Lu, Lin-Feng Tang, Feng‐Ling Tang, Rui-Qiu Zhu and 4 more

    32 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.003OpenAlex

    Show abstract

    PURPOSE: Radiation-induced intestinal injury (RIII) commonly occur during abdominal-pelvic cancer radiation therapy; however, no effective prophylactic or therapeutic agents are available to manage RIII currently. This study aimed to clarify the potential of probiotic consortium supplementation in alleviating RIII. METHODS AND MATERIALS: Male C57BL/6J mice were orally administered a probiotic mixture comprising Bifidobacterium longum BL21, Lactobacillus paracasei LC86, and Lactobacillus plantarum Lp90 for 30 days before exposure to 13 Gy of whole abdominal irradiation. The survival rates, clinical scores, and histologic changes in the intestines of mice were assessed. The impacts of probiotic consortium treatment on intestinal stem cell proliferation, differentiation, and epithelial barrier function; oxidative stress; and inflammatory cytokines were evaluated. A comprehensive examination of the gut microbiota composition was conducted through 16S rRNA sequencing, while changes in metabolites were identified using liquid chromatography-mass spectrometry. RESULTS: The probiotic…

  20. 23
    top 0.8%

    Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy

    Melissa O’Neil, Joanna M. Laba, Timothy K. Nguyen, Michael I. Lock, Christopher D. Goodman and 9 more

    31 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.005OpenAlex

    Show abstract

    PURPOSE: Using diagnostic computed tomography (dCT) scans instead of CT simulation (CTsim) scans can increase departmental efficiency and reduce patient burden. The goal of the DART trial was to assess the efficacy and acceptability of dCT-based planning workflows with a focus on patient experiences, plan deliverability and adequacy of target coverage, and workflows. METHODS AND MATERIALS: Patients undergoing same-day CTsim and treatment for palliative radiation therapy to thoracic, abdominopelvic, or proximal limb targets with a recent dCT (within 28 days) in a reproducible position were eligible. After stratifying by target type (bone or soft tissue vs. visceral), participants were randomized (1:2 ratio) between CTsim-based (CTsim arm) vs. dCT-based planning (dCT arm). The primary endpoint was time in center (TIC), defined as total time spent in the cancer center on first day of treatment, from first radiation department appointment to first fraction completion. Secondary endpoints included plan deliverability, adequacy of target coverage, and stakeholder acceptability. RESULTS:…

  21. 24
    top 0.9%

    Quality and Safety Considerations for Adaptive Radiation Therapy: An ASTRO White Paper

    Indrin J. Chetty, Bin Cai, Michael David Chuong, Samantha L. Dawes, William Adrian Hall and 8 more

    28 citationsdoi:10.1016/j.ijrobp.2024.10.011OpenAlex

  22. 25
    top 0.9%

    Toward Clinical-Grade Evaluation of Large Language Models

    Amy Catherine Moreno, Danielle S. Bitterman

    28 citationsOpen accessdoi:10.1016/j.ijrobp.2023.11.012OpenAlex

  23. 26
    top 0.9%
  24. 27
    top 1%

    NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy

    Nina Niu Sanford, Amol Kumar Narang, Todd Anthony Aguilera, Michael Frederick Bassetti, Michael David Chuong and 17 more

    27 citationsOpen access (OTHER-OA)doi:10.1016/j.ijrobp.2024.10.026OpenAlex

  25. 28
    top 1%

    Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial

    Jay Paul Reddy, Alexander Dean Sherry, Bryan M. Fellman, Suyu Liu, Tharakeswara Kumar Bathala and 19 more

    27 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.030OpenAlex

  26. 30
    top 1.1%

    Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review

    Saurav Verma, Sympascho Young, Gabriel Boldt, Phillip Blanchette, Michael I. Lock and 2 more

    27 citationsdoi:10.1016/j.ijrobp.2024.01.001OpenAlex

  27. 31
    top 1.1%

    Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

    Juliette Thariat, M. Bosset, Antoine Falcoz, Déwi Vernerey, Y. Pointreau and 25 more

    26 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.084OpenAlex

    Show abstract

    PURPOSE: Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative radiation therapy (SABR). Evidence to support this paradigm is scarce in squamous cell carcinoma of the head and neck (HNSCC). The multicenter open-label randomized GORTEC 2014-04 (NCT03070366) phase 2 study assesses survival without definitive quality of life (QoL) deterioration of omitting upfront chemotherapy in oligometastatic patients with HNSCC using SABR alone, in the French Head and Neck Intergroup. METHODS AND MATERIALS: Eligible participants (≥18 years old with 1-3 oligometastases, the Eastern Cooperative Oncology Group score 0-2) were randomly assigned (1:1) to receive chemo-SABR or SABR alone. Salvage treatments were left to the physician's appreciation. The standard therapy was considered to be systemic therapy and SABR (chemo-SABR; EXTREME regimen [5 fluorouracil/platinum/cetuximab]). The primary endpoint was 1-year (±3 months) overall survival rate without definitive deterioration (ie, without subsequent better QoL score) of the global European Organisation for…

  28. 32
    top 1.2%

    Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy

    Daniel Y. Song, Mateusz Dabkowski, Paulo Costa, Rizwan Nurani, Michael Kos and 11 more

    26 citationsdoi:10.1016/j.ijrobp.2024.07.2145OpenAlex

  29. 33
    top 1.2%

    Auto-delineation of Treatment Target Volume for Radiation Therapy Using Large Language Model-Aided Multimodal Learning

    Praveenbalaji Rajendran, Yizheng Chen, Liang Qiu, Thomas Niedermayr, Wu Liu and 9 more

    25 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.2149OpenAlex

  30. 35
    top 1.3%

    Differential Remodeling of the Oxylipin Pool After FLASH Versus Conventional Dose-Rate Irradiation In Vitro and In Vivo

    Lucie Portier, Patricia Daira, Baptiste Fourmaux, Sophie Heinrich, Margaux Becerra and 7 more

    25 citationsdoi:10.1016/j.ijrobp.2024.01.210OpenAlex

  31. 36
    top 1.3%

    Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care

    Thilo Schuler, Stephanie Roderick, Shelley Wong, Alannah Kejda, Kylie Grimberg and 16 more

    24 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.09.041OpenAlex

    Show abstract

    PURPOSE: The feasibility of simulation-free radiation therapy (SFRT) has been demonstrated but information regarding its routine care impact and scalability is lacking. METHODS AND MATERIALS: In this single-institution, retrospective cohort study, all patients receiving palliative radiation therapy at an Australian tertiary cancer center were eligible for consideration of SFRT unless mask immobilization, a stereotactic technique, or a definitive dose was indicated. Coprimary endpoints were SFRT utilization, impact on consultation-to-RT time, and on-couch treatment duration. Timing metrics were compared with a contemporary local cohort that received simulation-based palliative radiation therapy using unadjusted Wilcoxon rank-sum tests and a propensity score-matched regression. Electronic patient-reported outcomes captured 2-week toxicity and pain response. RESULTS: Between April 2018 and February 2024, 2849 palliative radiation courses were delivered, of which 1904 were eligible. Of the 1904 courses, 1000 (52.5% SFRT utilization) received SFRT, including 668 using intensity-modulated…

  32. 38
    top 1.4%

    A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy

    Juanita Mary Crook, Nikitha Moideen, Greg Arbour, Felipe Castro, Cynthia Araujo and 8 more

    24 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.02.064OpenAlex

    Show abstract

    PURPOSE: To compare health-related quality of life (QoL) in urinary, bowel, and sexual domains after combined external beam radiation therapy (EBRT) and either low-dose rate (LDR) or high-dose rate (HDR) prostate brachytherapy (BT). METHODS AND MATERIALS: Eligible men with intermediate or high-risk prostate cancer treated with combined pelvic EBRT and BT were randomly assigned to either HDR (15 Gy) or LDR (110 Gy) boost. International Prostate Symptom Score, Index of Erectile Function, and Expanded Prostate Cancer Composite were collected at baseline, 1, 3, 6, and 12 months, every 6 months to 3 years and then annually along with prostate-specific antigen/testosterone. Fisher's exact test compared categorical variables and the Mann-Whitney U test Expanded Prostate Cancer Index Composite (EPIC) domain scores. RESULTS: From January 2014 to December 2019, a random number generator assigned 195 men: 108 to HDR and 87 to LDR. Median age was 71 years. Risk group was high in 57% and unfavorable intermediate in 43%. Androgen deprivation (used in 74%) began with 3 months neoadjuvant and…

  33. 39
    top 1.4%

    Multi-Institutional Audit of FLASH and Conventional Dosimetry With a 3D Printed Anatomically Realistic Mouse Phantom

    Muhammad Ramish Ashraf, Stavros Melemenidis, Kevin Liu, Veljko Grilj, Jeannette Jansen and 20 more

    24 citationsOpen accessdoi:10.1016/j.ijrobp.2024.03.017OpenAlex

  34. 40
    top 1.4%

    Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost

    Allison Y. Zhong, Asona J. Lui, Svetlana Kuznetsova, Karoline Kallis, Christopher C. Conlin and 12 more

    24 citationsOpen accessdoi:10.1016/j.ijrobp.2024.06.007OpenAlex

  35. 41
    top 1.5%

    Refining Treatment Planning in STereotactic Arrhythmia Radioablation: Benchmark Results and Consensus Statement From the STOPSTORM.eu Consortium

    Valeria Trojani, Melanie Grehn, Andrea Botti, Brian V. Balgobind, A. Savini and 25 more

    23 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2331OpenAlex

    Show abstract

    PURPOSE: STereotactic Arrhythmia Radioablation (STAR) showed promising results in patients with refractory ventricular tachycardia. However, clinical data are scarce and heterogeneous. The STOPSTORM.eu consortium was established to investigate and harmonize STAR in Europe. The primary goal of this benchmark study was to investigate current treatment planning practice within the STOPSTORM project as a baseline for future harmonization. METHODS AND MATERIALS: Planning target volumes (PTVs) overlapping extracardiac organs-at-risk and/or cardiac substructures were generated for 3 STAR cases. Participating centers were asked to create single-fraction treatment plans with 25 Gy dose prescriptions based on in-house clinical practice. All treatment plans were reviewed by an expert panel and quantitative crowd knowledge-based analysis was performed with independent software using descriptive statistics for International Commission on Radiation Units and Measurements report 91 relevant parameters and crowd dose-volume histograms. Thereafter, treatment planning consensus statements were…

  36. 42
    top 1.5%

    The Effect of Radiation Treatment of Solid Tumors on Neutrophil Infiltration and Function: A Systematic Review

    Léon Raymakers, Thijs J. Demmers, Gert J. Meijer, Izaak Quintus Molenaar, Hjalmar C. van Santvoort and 4 more

    23 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2141OpenAlex

    Show abstract

    Radiation therapy (RT) initiates a local and systemic immune response which can induce antitumor immunity and improve immunotherapy efficacy. Neutrophils are among the first immune cells that infiltrate tumors after RT and are suggested to be essential for the initial antitumor immune response. However, neutrophils in tumors are associated with poor outcomes and RT-induced neutrophil infiltration could also change the composition of the tumor microenvironment (TME) in favor of tumor progression. To improve RT efficacy for patients with cancer it is important to understand the interplay between RT and neutrophils. Here, we review the literature on how RT affects the infiltration and function of neutrophils in the TME of solid tumors, using both patients studies and preclinical murine in vivo models. In general, it was found that neutrophil levels increase and reach maximal levels in the first days after RT and can remain elevated up to 3 weeks. Most studies report an immunosuppressive role of neutrophils in the TME after RT, caused by upregulated expression of neutrophil indoleamine…

  37. 43
    top 1.5%

    Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial

    Binnaz Yasar, Yae‐Eun Suh, Ewan Chapman, Luke Nicholls, Daniel Henderson and 9 more

    23 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.009OpenAlex

    Show abstract

    PURPOSE: Dose-escalated radiation therapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease while limiting toxicity. This study evaluated the toxicity and quality of life (QoL) with CyberKnife-based SBRT and simultaneous integrated boost in localized prostate cancer. METHODS AND MATERIALS: Eligible participants included newly diagnosed, biopsy-proven unfavorable intermediate- to high-risk localized prostate cancer (at least 1 of the following: Gleason ≥4+3, magnetic resonance imaging(MRI)-defined T3a N0, prostate-specific antigen ≥20) with up to 2 MRI-identified DILs. Participants received 36.25 Gy in 5 fractions on alternative days with a simultaneous boost to DIL up to 47.5 Gy as allowed by organ-at-risk constraints delivered by CyberKnife. All participants received androgen deprivation therapy. The primary outcome measure was acute grade 2+ genitourinary toxicity. Acute and late…

  38. 44
    top 1.6%

    Thoracic Proton Minibeam Radiation Therapy: Tissue Preservation and Survival Advantage Over Conventional Proton Therapy

    Annaïg Bertho, Ramón Ortiz, Mathieu Maurin, Marjorie Juchaux, Cristèle Gilbert and 6 more

    22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.011OpenAlex

    Show abstract

    PURPOSE: Proton minibeam radiation therapy (pMBRT) is an innovative radiation therapy approach that highly modulates the spatial dimension of the dose delivery using narrow, parallel, and submillimetric proton beamlets. pMBRT has proven its remarkable healthy tissue preservation in the brain and skin. This study assesses the potential advantages of pMBRT for thoracic irradiations compared with conventional radiation therapy in terms of normal tissue toxicity. The challenge here was the influence of respiratory motion on the typical peak and valley dose patterns of pMBRT and its potential biologic effect. METHODS AND MATERIALS: The whole thorax of naïve C57BL/6 mice received one fraction of high dose (18 Gy) pMBRT or conventional proton therapy (CPT) without any respiratory control. The development of radiation-induced pulmonary fibrosis was longitudinally monitored using cone beam computed tomography. Anatomopathologic analysis was carried out at 9 months postirradiation and focused on the reaction of the lungs' parenchyma and the response of cell types involved in the development…

  39. 45
    top 1.6%

    Incorporation of Functional Lung Imaging Into Radiation Therapy Planning in Patients With Lung Cancer: A Systematic Review and Meta-Analysis

    Julie Midroni, Rohan Salunkhe, Zhihui Liu, Ronald Chow, Gabriel Boldt and 4 more

    22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.001OpenAlex

    Show abstract

    Our purpose was to provide an understanding of current functional lung imaging (FLI) techniques and their potential to improve dosimetry and outcomes for patients with lung cancer receiving radiation therapy (RT). Excerpta Medica dataBASE (EMBASE), PubMed, and Cochrane Library were searched from 1990 until April 2023. Articles were included if they reported on FLI in one of: techniques, incorporation into RT planning for lung cancer, or quantification of RT-related outcomes for patients with lung cancer. Studies involving all RT modalities, including stereotactic body RT and particle therapy, were included. Meta-analyses were conducted to investigate differences in dose-function parameters between anatomic and functional RT planning techniques, as well as to investigate correlations of dose-function parameters with grade 2+ radiation pneumonitis (RP). One hundred seventy-eight studies were included in the narrative synthesis. We report on FLI modalities, dose-response quantification, functional lung (FL) definitions, FL avoidance techniques, and correlations between FL irradiation…

  40. 46
    top 1.6%

    Brain and Brain Stem Necrosis After Reirradiation for Recurrent Childhood Primary Central Nervous System Tumors: A PENTEC Comprehensive Review

    Thankamma Ajithkumar, Michele Avanzo, Ellen D. Yorke, Derek S. Tsang, Michael T. Milano and 11 more

    22 citationsdoi:10.1016/j.ijrobp.2023.12.043OpenAlex

  41. 47
    top 1.7%

    Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy

    Julian Philipp Layer, Ehab Shiban, Stefanie Brehmer, Christian Diehl, Douglas Guedes de Castro and 14 more

    22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.01.009OpenAlex

    Show abstract

    PURPOSE: After surgical resection of brain metastases (BMs), intraoperative radiation therapy (IORT) provides a promising alternative to adjuvant external beam radiation therapy by enabling superior organ-at-risk preservation, reduction of in-hospital times, and timely admission to subsequent systemic treatments, which increasingly comprise novel targeted immunotherapeutic approaches. We sought to assess the safety and efficacy of IORT in combination with immune checkpoint inhibitors (ICIs) and other targeted therapies (TTs). METHODS AND MATERIALS: In a multicentric approach incorporating individual patient data from 6 international IORT centers, all patients with BMs undergoing IORT were retrospectively assessed for combinatorial treatment with ICIs/TTs and evaluated for toxicity and cumulative rates, including wound dehiscence, radiation necrosis, leptomeningeal spread, local control, distant brain progression (DBP), and estimated overall survival. RESULTS: In total, 103 lesions with a median diameter of 34 mm receiving IORT combined with immunomodulatory systemic treatment or…

  42. 48
    top 1.7%

    Characterization of a Time-Resolved, Real-Time Scintillation Dosimetry System for Ultra-High Dose-Rate Radiation Therapy Applications

    Alexander Baikalov, Daline Tho, Kevin Liu, Stefan H. Bartzsch, Sam A. Beddar and 1 more

    21 citationsOpen accessdoi:10.1016/j.ijrobp.2024.11.092OpenAlex

  43. 49
    top 1.7%

    FLASH Bragg-Peak Irradiation With a Therapeutic Carbon Ion Beam: First In Vivo Results

    Walter Tinganelli, Anggraeini Puspitasari-Kokko, Olga Sokol, Alexander Helm, Palma Simoniello and 14 more

    21 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.089OpenAlex

    Show abstract

    PURPOSE: In recent years, ultra-high dose rate (UHDR) irradiation has emerged as a promising innovative approach to cancer treatment. Characteristic feature of this regimen, commonly referred to as FLASH effect, demonstrated primarily for electrons, photons, or protons, is the improved normal tissue sparing, whereas the tumor control is similar to the one of the conventional dose-rate (CDR) treatments. The FLASH mechanism is, however, unknown. One major question is whether this effect is maintained when using densely ionizing (high-LET) heavy nuclei. METHODS MATERIALS: C beam using an osteosarcoma mouse model. RESULTS: We show that UHDR irradiation was less toxic in the normal tissue compared with CDR while maintaining tumor control. The immune activation was also comparable in UHDR and CDR groups. Both UHDR and CDR exposures steered the metagenome toward a balanced state. CONCLUSIONS: These results suggest that the UHDR irradiations can improve the safety and effectiveness of heavy ion therapy, and provide a crucial benchmark for current mechanistic FLASH models. However,…

  44. 50
    top 1.8%

    Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial

    Gabriella Macchia, Maura Campitelli, Donato Pezzulla, Simona Lucci, Andrei Fodor and 25 more

    21 citationsdoi:10.1016/j.ijrobp.2024.09.036OpenAlex

  45. 51
    top 1.8%

    Artificial Intelligence-Empowered Multistep Integrated Radiation Therapy Workflow for Nasopharyngeal Carcinoma

    Yu‐Xian Yang, Xin Yang, Xiaobo Jiang, Lin Li, Guangyu Wang and 25 more

    20 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.096OpenAlex

    Show abstract

    PURPOSE: To establish an artificial intelligence (AI)-empowered multistep integrated (MSI) radiation therapy (RT) workflow for patients with nasopharyngeal carcinoma (NPC) and evaluate its feasibility and clinical performance. METHODS AND MATERIALS: Patients with NPC scheduled for MSI RT workflow were prospectively enrolled. This workflow integrates RT procedures from computed tomography (CT) scan to beam delivery, all performed with the patient on the treatment couch. Workflow performance, tumor response, patient-reported acute toxicities, and quality of life were evaluated. RESULTS: From March 2022 to October 2023, 120 newly diagnosed, nonmetastatic patients with NPC were enrolled. Of these, 117 completed the workflow with a median duration of 23.2 minutes (range, 16.3-45.8). Median translation errors were 0.2 mm (from CT scan to planning approval) and 0.1 mm (during beam delivery). AI-generated contours required minimal revision for the high-risk clinical target volume and organs at risk, minor revision for the involved cervical lymph nodes and low-risk clinical target volume…

  46. 53
    top 1.9%

    Intracellular Oxygen Transient Quantification in Vivo During Ultra-High Dose Rate FLASH Radiation Therapy

    Arthur F. Pétusseau, Megan Clark, Petr Brůža, David J. Gladstone, Brian W. Pogue

    20 citationsOpen accessdoi:10.1016/j.ijrobp.2024.04.068OpenAlex

  47. 54
    top 1.9%

    Vestibular Schwannoma International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS Study

    Othman Bin-Alamer, Hussam Abou‐Al‐Shaar, Selçuk Peker, Yavuz Samancı, Isabelle Pelcher and 25 more

    20 citationsdoi:10.1016/j.ijrobp.2024.04.004OpenAlex

  48. 55
    top 2%

    Cluster-Based Toxicity Estimation of Osteoradionecrosis Via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification

    Seyedmohammadhossein Hosseinian, Mehdi Hemmati, Cem Dede, Travis C. Salzillo, Lisanne Vania van Dijk and 4 more

    20 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.02.021OpenAlex

    Show abstract

    PURPOSE: Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference by exploiting structural properties of data and provide a clinically reliable model for ORN risk evaluation through an unsupervised-learning analysis that incorporates the whole radiation dose distribution on the mandible. METHODS AND MATERIALS: The analysis was conducted on retrospective data of 1259 patients with head and neck cancer treated at The University of Texas MD Anderson Cancer Center between 2005 and 2015. During a minimum 12-month posttherapy follow-up period, 173 patients in this cohort (13.7%) developed ORN (grades I to IV). The (structural) clusters of mandibular dose-volume histograms (DVHs) for these patients were identified using the K-means clustering method. A soft-margin support vector machine was used to determine the cluster borders and partition the dose-volume space. The risk of ORN for each dose-volume region was calculated based on incidence rates…

  49. 56
    top 2%

    Patient-Specific Deep Learning Tracking Framework for Real-Time 2D Target Localization in Magnetic Resonance Imaging-Guided Radiation Therapy

    Elia Lombardo, Laura Velezmoro, Sebastian Norbert Marschner, Moritz Rabe, Claudia Tejero and 8 more

    19 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.10.021OpenAlex

    Show abstract

    Purpose We propose a tumor tracking framework for 2D cine magnetic resonance imaging (MRI) based on a pair of deep learning (DL) models relying on patient-specific (PS) training. Methods and Materials The chosen DL models are: (1) an image registration transformer and (2) an auto-segmentation convolutional neural network (CNN). We collected over 1,400,000 cine MRI frames from 219 patients treated on a 0.35 T MRI-linac plus 7500 frames from additional 35 patients that were manually labeled and subdivided into fine-tuning, validation, and testing sets. The transformer was first trained on the unlabeled data (without segmentations). We then continued training (with segmentations) either on the fine-tuning set or for PS models based on 8 randomly selected frames from the first 5 seconds of each patient's cine MRI. The PS auto-segmentation CNN was trained from scratch with the same 8 frames for each patient, without pre-training. Furthermore, we implemented B-spline image registration as a conventional model, as well as different baselines. Output segmentations of all models were…

  50. 59
    top 2.1%

    A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiation Therapy Using Diagnostic MRI-Based and Online Adaptive Planning

    Kylie H. Kang, Alex T. Price, Francisco J. Reynoso, Eric Laugeman, Eric D. Morris and 8 more

    19 citationsdoi:10.1016/j.ijrobp.2024.03.039OpenAlex

  51. 60
    top 2.1%
  52. 61
    top 2.2%
  53. 62
    top 2.2%
  54. 64
    top 2.3%

    The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial

    Rachel Glicksman, Srinivas Raman, Xiang Y. Ye, Philippe Lucien Bedard, Scott Victor Bratman and 11 more

    18 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.09.002OpenAlex

    Show abstract

    PURPOSE: In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changing systemic therapy (ST), stereotactic body radiation therapy (SBRT) is being explored as an alternative local therapy targeting the sites of progression. METHODS AND MATERIALS: RADIANT (NCT04122469) was a single-center phase 2 study of patients with metastatic genitourinary (GU), breast, and gastrointestinal (GI) cancers, receiving ST for ≥3 months, with radiographic OP disease in ≤5 sites. Patients received SBRT for all OP disease in 1 to 5 fractions and were maintained on ST. The primary endpoint was the cumulative incidence of change in ST, which was estimated using the Aalen-Johansen method. Secondary endpoints included progression-free survival (PFS) and overall survival estimated using the Kaplan-Meier method, as well as toxicity and health-related quality of life. Comparisons between diagnosis groups were done using the log-rank test. A 2-sided p value <.05 was…

  55. 65
    top 2.3%

    Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease

    Timothy K. Nguyen, Sherif Ramadan, David A. Palma, Mark Thomas Corkum, Melissa O’Neil and 10 more

    18 citationsdoi:10.1016/j.ijrobp.2024.06.033OpenAlex

  56. 67
    top 2.4%

    USP11 Exacerbates Radiation-Induced Pneumonitis by Activating Endothelial Cell Inflammatory Response via OTUD5-STING Signaling

    Yiting Tang, Ting-Ya Wang, Liming Gu, Ying Xu, Yang Zhao and 5 more

    18 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.01.220OpenAlex

    Show abstract

    Purpose Radiation-induced pneumonitis (RIP) seriously limits the application of radiation therapy in the treatment of thoracic tumors, and its etiology and pathogenesis remain elusive. This study aimed to elucidate the role of ubiquitin-specific peptidase 11 (USP11) in the progression of RIP and the associated underlying mechanisms. Methods and Materials Changes in cytokines and infiltrated immune cells were detected by enzyme-linked immunosorbent assays and immunohistochemistry after exposure to 20 Gy x-ray with whole-thorax irradiation. The effects of USP11 expression on endothelial cell proliferation and apoptosis were analyzed by costaining of CD31/Ki67 and CD31/caspase-3 in vivo, and the production of cytokines and reactive oxygen species was confirmed by reverse-transcription polymerase chain reaction and flow cytometry in vitro . Comprehensive proteome and ubiquitinome analyses were used for USP11 substrate screening after radiation. Results were verified by Western blotting and coimmunoprecipitation experiments. Recombinant adeno-associated virus lung vectors expressing…

  57. 68
    top 2.4%

    Deep Learning Auto-Segmentation Network for Pediatric Computed Tomography Data Sets: Can We Extrapolate From Adults?

    Kartik Kumar, Adam Unjin Yeo, Lachlan McIntosh, Tomas Kron, Greg Wheeler and 1 more

    18 citationsdoi:10.1016/j.ijrobp.2024.01.201OpenAlex

  58. 69
    top 2.4%

    Radiation Therapy for Meningiomas – Where Do We Stand and What's on the Horizon?

    Felix Ehret, Leon El Baya, Sara Erridge, Marc R. Bussière, Joost J.C. Verhoeff and 4 more

    17 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.10.034OpenAlex

    Show abstract

    Radiation therapy, including conventionally fractionated external beam radiation therapy, stereotactic radiosurgery, and fractionated stereotactic radiation therapy, is a cornerstone in the interdisciplinary management of meningiomas. Recent advances in radiation oncology and also in other fields, such as neuropathology and imaging, have various implications for meningioma radiation therapy. This review aims to summarize current and anticipated developments, as well as active clinical trials related to the use of radiation therapy for meningiomas. In imaging, positron emission tomography has proven valuable for assessing the spatial extension of meningiomas and may enhance target delineation, treatment response monitoring, and recurrence assessment after radiation therapy. Particle therapy, including protons and carbon ions, as well as stereotactic radiosurgery and fractionated stereotactic radiation therapy, allow for conformal treatments that permit dose escalation in selected patients with high-grade meningiomas. Additionally, emerging integrated molecular and genetic…

  59. 70
    top 2.5%

    Stereotactic Radiation Therapy in 3 Fractions for T1 Glottic Cancer

    Giuseppe Sanguineti, Pasqualina D’Urso, Marta Bottero, Alessia Farneti, Lucia Goanta and 2 more

    17 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.09.051OpenAlex

    Show abstract

    PURPOSE/OBJECTIVE(S): To report the results of a phases 1 and 2 study on stereotactic body radiation therapy (SBRT) for early glottic cancer. METHODS AND MATERIALS: This a prospective study at a single institution enrolling patients with T1 glottic cancer. The true vocal cords (TVCs) were divided into thirds and the third(s) containing disease prescribed 36 Gy in 3 fractions. The portions of the TVCs next to the involved one were planned to receive 30 Gy in 3 fxs. SBRT was delivered by a linear accelerator-based approach using multiple arcs. Toxicity was scored by Common Terminology Criteria for Adverse Events and late events were considered those occurring 3 months after SBRT. Voice quality was investigated by the Voice Handicap Index at regular intervals. The planned sample size was 75 patients. RESULTS: Accrual was discontinued after 33 patients because of concerns for late toxicity. T stage was as follows: T1a: 23 patients (69.7%); T1b: 10 patients (30.3%). All patients received the planned treatment and the median follow-up time was 51.5 months (IQR, 47.9-61.0 months). At last…

  60. 71
    top 2.5%

    The Value and Safety of Adjuvant Radiation Therapy After Radical Cystectomy in Locally Advanced Urothelial Bladder Cancer: A Controlled Randomized Study

    Mohamed S. Zaghloul, Ahmed Khaled Alnagmy, Hatem Aboul Kassem, Mohamed M. Abdel Hakim, Ahmed Abdallah and 3 more

    17 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.012OpenAlex

  61. 72
    top 2.5%
  62. 74
    top 2.6%

    Oxygen Consumption In Vivo by Ultra-High Dose Rate Electron Irradiation Depends Upon Baseline Tissue Oxygenation

    Jacob P. Sunnerberg, Armin D. Tavakkoli, Arthur F. Pétusseau, Noah J. Daniel, Austin M. Sloop and 8 more

    16 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.018OpenAlex

  63. 75
    top 2.6%

    Proton Therapy for Spinal Tumors: A Consensus Statement From the Particle Therapy Cooperative Group

    Arpit M. Chhabra, James William Snider III, Adam J. Kole, Markus Stock, Adam L. Holtzman and 13 more

    16 citationsdoi:10.1016/j.ijrobp.2024.04.007OpenAlex

  64. 76
    top 2.7%

    Three-Dimensional Deep Learning Normal Tissue Complication Probability Model to Predict Late Xerostomia in Patients With Head and Neck Cancer

    Hung Chu, Suzanne P.M. de Vette, Hendrike Neh, Nanna Maria Sijtsema, Roel J.H.M. Steenbakkers and 5 more

    16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2334OpenAlex

    Show abstract

    Purpose Conventional normal tissue complication probability (NTCP) models for patients with head and neck cancer are typically based on single-value variables, which, for radiation-induced xerostomia, are baseline xerostomia and mean salivary gland doses. This study aimed to improve the prediction of late xerostomia by using 3-dimensional information from radiation dose distributions, computed tomography imaging, organ-at-risk segmentations, and clinical variables with deep learning (DL). Methods and Materials An international cohort of 1208 patients with head and neck cancer from 2 institutes was used to train and twice validate DL models (deep convolutional neural network, EfficientNet-v2, and ResNet) with 3-dimensional dose distribution, computed tomography scan, organ-at-risk segmentations, baseline xerostomia score, sex, and age as input. The NTCP endpoint was moderate-to-severe xerostomia 12 months postradiation therapy. The DL models' prediction performance was compared with a reference model: a recently published xerostomia NTCP model that used baseline xerostomia score and…

  65. 77
    top 2.7%

    Preoperative Magnetic Resonance Guided Single-Dose Partial Breast Irradiation: 5-Year Results of the Prospective Single-Arm ABLATIVE Trial

    Yasmin A. Civil, Jeanine E. Vasmel, Ramona K. Charaghvandi, Anette C. Houweling, Celien P.H. Vreuls and 12 more

    16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2326OpenAlex

    Show abstract

    PURPOSE: Preoperative partial breast irradiation (PBI) can increase accuracy of target volume definition and decrease irradiated volumes compared with postoperative PBI. In the ABLATIVE trial (NCT02316561), 15 of 36 patients achieved pathologic complete response 6 to 8 months after preoperative PBI and breast-conserving surgery (BCS). We now present the 5-year results. METHODS AND MATERIALS: The ABLATIVE trial is a Dutch prospective cohort study conducted in 4 hospitals. Women aged ≥50 years with unifocal, nonlobular breast cancer, estrogen receptor-positive, HER2-negative, and a tumor negative sentinel node were treated between 2015 and 2018 with preoperative single-dose PBI followed by BCS after 6 or 8 months. The primary endpoint was pathologic complete response. Secondary endpoints were annually evaluated oncological outcomes, toxicity, cosmetic outcome (assessed by patients and physicians), and quality of life. RESULTS: Thirty-six patients were treated with BCS 6 (n = 15) and 8 (n = 21) months following PBI. Median tumor size was 13 mm (IQR 9-16 mm). After a median follow-up of…

  66. 78
    top 2.7%

    Clinical Implementation and Dosimetric Evaluation of a Robust Proton Lattice Planning Strategy Using Primary and Robust Complementary Beams

    Sina Mossahebi, Jason K. Molitoris, Yannick P. Poirier, Jenna Jatczak, Baoshe Zhang and 4 more

    16 citationsdoi:10.1016/j.ijrobp.2024.06.009OpenAlex

  67. 79
    top 2.8%

    Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy

    Sarah T. Arron, Javier Cañueto, Jennifer J. Siegel, Alison L. Fitzgerald, Anesh Prasai and 2 more

    16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.05.022OpenAlex

    Show abstract

    PURPOSE: Adjuvant radiation therapy (ART) for cutaneous squamous cell carcinoma is recommended based on a number of wide-ranging clinicopathologic features, which encompass a broad array of patients. The 40-gene expression profile (GEP) test classifies cutaneous squamous cell carcinoma tumors into low (class 1), higher (class 2A), or highest (class 2B) risk of nodal and/or distant metastasis. This study's hypotheses are as follows: (1) local recurrence is associated with metastatic disease progression and (2) 40-GEP, by identifying high risk for metastasis, could predict a metastasis-specific benefit from ART. METHODS AND MATERIALS: Samples were obtained from 920 patients (ART-untreated: 496 class 1, 335 class 2A, and 33 class 2B; ART-treated: 11 class 1, 35 class 2A, and 10 class 2B) who were matched on clinical risk factors and stratified by ART status to create 49 matched patient strata. To control for the variety of characteristics and treatment selection bias, randomly sampled pairs of matched ART and non-ART patients comprising 10,000 resampled cohorts were each analyzed for…

  68. 80
    top 2.8%

    Clinical Experience With an Offline Adaptive Radiation Therapy Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection

    Michalis Aristophanous, Eric Aliotta, Phillip Lichtenwalner, Shira Abraham, Mohammad Nehmeh and 12 more

    16 citationsOpen accessdoi:10.1016/j.ijrobp.2024.02.016OpenAlex

  69. 82
    top 2.9%

    Generalizable Magnetic Resonance Imaging-based Nasopharyngeal Carcinoma Delineation: Bridging Gaps Across Multiple Centers and Raters With Active Learning

    Xiangde Luo, Hongqiu Wang, Jinfeng Xu, Lu Li, Yue Zhao and 8 more

    15 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.11.064OpenAlex

    Show abstract

    PURPOSE: To develop a deep learning method exploiting active learning and source-free domain adaptation for gross tumor volume delineation in nasopharyngeal carcinoma (NPC), addressing the variability and inaccuracy when deploying segmentation models in multicenter and multirater settings. METHODS AND MATERIALS: One thousand fifty-seven magnetic resonance imaging scans of patients with NPC from 5 hospitals were retrospectively collected and annotated by experts from the same medical group with consensus for multicenter adaptation evaluation. One data set was used for model development (source domain), with the remaining 4 for adaptation testing (target domains). Meanwhile, another set of 170 patients with NPC, with annotations delineated by 4 independent experts, was created for multirater adaptation evaluation. We evaluated the pretrained model's migration ability to the 4 multicenter and 4 multirater target domains. Dice similarity coefficient (DSC), 95% Hausdorff distance (HD95), and other metrics were used for quantitative evaluations. RESULTS: In the adaptation of dataset5 to…

  70. 83
    top 2.9%

    Assessment of Photon-Counting Computed Tomography for Quantitative Imaging in Radiation Therapy

    Jens Zimmerman, Gavin G. Poludniowski

    15 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.069OpenAlex

    Show abstract

    PURPOSE: To test a first-generation clinical photon-counting computed tomography (PCCT) scanner's capabilities to characterize materials in an anthropomorphic head phantom for radiation therapy purposes. METHODS AND MATERIALS: A CIRS 731-HN head-and-neck phantom (CIRS/SunNuclear) was scanned on a NAEOTOM Alpha PCCT and a SOMATOM Definition AS+ with single-energy and dual-energy CT techniques (SECT and DECT, respectively), both scanners manufactured by Siemens (Siemens Healthineers). A method was developed to derive relative electron density (RED) and effective atomic number (EAN) from linear attenuation coefficients (LACs) of virtual mono-energetic images and applied for the PCCT and DECT data. For DECT, Siemens' syngo.via "Rho/Z"-algorithm was also used. Proton stopping-power ratios (SPRs) were calculated based on RED/EAN with the Bethe equation. For SECT, a stoichiometric calibration to SPR was used. Nine materials in the phantom were segmented, excluding border pixels. Distributions and root-mean-square deviations within the material regions were evaluated for LAC, RED/EAN, and…

  71. 84
    top 3%

    Dynamics of Daily Glioblastoma Evolution During Chemoradiation Therapy on the 0.35T Magnetic Resonance Imaging-Linear Accelerator

    Kaylie Cullison, Kayla Samimi, Jonathan B. Bell, Danilo Maziero, Alessandro Valderrama and 9 more

    15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.09.028OpenAlex

  72. 85
    top 3%

    Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial

    Vedang Murthy, Priyamvada Maitre, Ganesh Bakshi, Mahendra Pal, Maneesh Singh and 16 more

    15 citationsdoi:10.1016/j.ijrobp.2024.09.040OpenAlex

  73. 86
    top 3%

    Safety and Preliminary Efficacy of AZD1390 + Radiation Therapy for Glioblastoma

    J.T. Yang, Patrick Yung Wen, B.S. Imber, Jan Drappatz, R. Jena and 12 more

    15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.217OpenAlex

  74. 87
    top 3.1%
  75. 88
    top 3.1%

    MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial

    J. Detsky, Annie W. Chan, Daniel Moore-Palhares, John M. Hudson, James Stewart and 10 more

    15 citationsdoi:10.1016/j.ijrobp.2024.08.016OpenAlex

  76. 89
    top 3.1%

    Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer

    Pier Paolo Avolio, Ronald Kool, Bobby Shayegan, Gautier Marcq, Peter C. Black and 16 more

    15 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.08.036OpenAlex

    Show abstract

    PURPOSE: To compare the oncologic outcomes of patients with nonmetastatic muscle-invasive bladder cancer (MIBC) undergoing complete versus incomplete transurethral tumor resection (TURBT) before radiation therapy. METHODS AND MATERIALS: Patients with nonmetastatic MIBC who underwent curative-intent radiation therapy between 2002 and 2018 at 10 Canadian institutions were retrospectively evaluated. Inverse probability of treatment weighting was performed using baseline characteristics. Differences in survival outcomes by complete and incomplete TURBT were analyzed. RESULTS: Of the 757 patients included, 66% (498) had documentation of a complete and 34% (259) an incomplete TURBT. Before adjustment, 121 (47%) and 45 (9%) patients who underwent incomplete and complete TURBT, respectively, were diagnosed with cT3-4 tumor (P <.001). After weight-adjustment, all baseline cohort characteristics were balanced (absolute standardized differences < 0.1). The adjusted median follow-up was 27 months. Adjusted survival analyses showed no significant difference in 5-year overall survival (48% vs…

  77. 90
    top 3.2%

    Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE

    Supriya Chopra, Tjalling Bosse, Nanda Horeweg, Kedar Deodhar, Santosh G. Menon and 17 more

    15 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2316OpenAlex

    Show abstract

    PURPOSE: BIOEMBRACE was designed to study the impact of biomarkers in addition to clinicopathological factors on disease outcomes in patients treated with chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy (BT) for locally advanced cervical cancer in the EMBRACE study. METHODS AND MATERIALS: Between 2018 and 2021, 8 EMBRACE-I sites contributed tumor tissue for the immunohistochemistry of p16, PD-L1, and L1CAM. These biomarkers and clinicopathological factors (International Federation of Gynecology and Obstetrics 2009 stage, nodal status, histology, and necrosis on MRI) were analyzed to predict poor response at BT (high-risk clinical target volume [HR-CTV] ≥ 40 cc) at BT) and 5-year local control, pelvic control, and disease-free survival. Interaction between p16, PD-L1, radiation therapy dose (HR-CTV D90), and disease outcomes was investigated. Univariable and multivariable analyses were performed. RESULTS: Two hundred sixty-four patients were included. The median HR-CTV D90 was 89 Gy (86-95). P-16 positive status, PD-L1 > 1%, and L1CAM ≥ 10% was noted in…

  78. 91
    top 3.2%

    Enhancing Precision in Cardiac Segmentation for Magnetic Resonance-Guided Radiation Therapy Through Deep Learning

    Nicholas Summerfield, Eric D. Morris, Soumyanil Banerjee, Qisheng He, Ahmed I. Ghanem and 4 more

    15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.013OpenAlex

  79. 92
    top 3.2%

    Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial

    Qi Zhang, Shaonan Fan, Xiaohong Xu, Shisuo Du, Guangying Zhu and 10 more

    15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.030OpenAlex

    Show abstract

    PURPOSE: The standard treatment schedule for unresectable stage III non-small cell lung cancer (NSCLC) is chemotherapy with concurrent radiation therapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiation therapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiation therapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy. METHODS AND MATERIALS: In this randomized, multicenter, nonblinded phase 3 clinical trial, eligible patients were randomised at a 1:1 ratio to either the Hypo-RT group (60 Gy in 20 fractions) or Con-RT group (60 Gy in 30 fractions). All patients received 2 cycles of concurrent platinum-based chemotherapy plus 2 cycles of consolidation therapy. The primary endpoint was 3-year overall survival (OS) in the intention-to-treat population. The secondary endpoints were progression-free survival and treatment-related adverse events. RESULTS: A total…

  80. 94
    top 3.3%

    Outcome After Modern Proton Beam Therapy in Childhood Craniopharyngioma: Results of the Prospective Registry Study KiProReg

    Martin Bischoff, Dalia Ahmad Khalil, Sabine Frisch, Claus Maximilian Bäcker, Sarah Peters and 6 more

    15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.015OpenAlex

    Show abstract

    Background Craniopharyngiomas (CPs) are rare tumours of the sellar region often leading to significant comorbidities due to their close proximity to critical structures. Aim of this study was to analyse survival outcome and late toxicities after surgery and proton beam therapy (PBT) in childhood CPs. Patients and methods Within the prospective XXXX study (XXXX), data of 74 childhood patients with CP, receiving PBT between 08/2013-06/2022 were eligible. Late toxicities were analysed according to the grading system of CTCAE 4.0. Results : Median follow-up (FU) since first diagnosis was 4.3 years (range, 0.8-14.7). 75.7% of patients received PBT at time of disease progression or recurrence, whereas 24.3% as part of their primary therapy (definitive or adjuvant). Predominantly (85.1%), pencil beam scanning technique was used. Median total dose and initial tumour volume were 5400 cGyRBE (relative biological effectiveness) and 17.64 cm³ (range, 3.07-300.59), respectively. The estimated (±SE) 3-year overall survival, progression-free and cystic failure-free survival rate after PBT were…

  81. 95
    top 3.3%

    Linear Energy Transfer Measurements and Estimation of Relative Biological Effectiveness in Proton and Helium Ion Beams Using Fluorescent Nuclear Track Detectors

    Iván Domingo Muñoz, Daniel García-Calderón, Renato Félix‐Bautista, Lucas Norberto Burigo, Jeppe Brage Christensen and 6 more

    15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.02.047OpenAlex

    Show abstract

    Purpose To develop a methodology for assessing the linear energy transfer (LET) and relative biological effectiveness (RBE) in clinical proton and helium-ion beams using fluorescent nuclear track detectors (FNTDs). Methods and materials FNTDs were exposed behind solid water to proton and helium- ( 4 He-) ion spread-out Bragg peaks (SOBPs). Detectors were imaged with a confocal microscope, and the LET spectra were derived from the fluorescence intensity. The track- and dose-averaged LET (LET F and LET D , respectively) were calculated from the LET spectra. LET measurements were used as input on RBE-models to estimate the RBE. Human alveolar adenocarcinoma cells (A549) were exposed at the same positions as the FNTDs. The RBE was calculated from the resulting survival curves. All measurements were compared with Monte Carlo simulations. Results For protons, average relative differences between measurements and simulations were 6% and 19% for LET F and LET D , respectively. For helium ions the same differences were 11% for both quantities. The position of the experimental LET spectra…

  82. 97
    top 3.4%

    Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial

    Sarah E. Baker, Linden Lechner, Mitchell Liu, Jee Suk Chang, Ella Mae Cruz-Lim and 25 more

    15 citationsdoi:10.1016/j.ijrobp.2024.01.008OpenAlex

  83. 98
    top 3.4%

    A Prospective, Phase II Study of 177Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort

    Kenneth Wing Merrell, Derek Richard Johnson, Kimberly O. Steinert, Michael W. Ruff, W. Breen and 10 more

    14 citationsdoi:10.1016/j.ijrobp.2024.07.003OpenAlex

  84. 99
    top 3.5%

    Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-Based Autosegmentation in Pencil Beam Scanning Proton Therapy

    Hongying Feng, Jie Shan, Carlos Vargas, Sameer R. Keole, Jean-Claude M. Rwigema and 9 more

    14 citationsdoi:10.1016/j.ijrobp.2024.09.032OpenAlex

  85. 100
    top 3.5%

    Experience of Implementing Deep Learning-Based Automatic Contouring in Breast Radiation Therapy Planning: Insights From Over 2000 Cases

    Byung Min Lee, Jin Sung Kim, Yongjin Chang, Seo Hee Choi, Jong Won Park and 4 more

    14 citationsdoi:10.1016/j.ijrobp.2024.02.041OpenAlex

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to International Journal of Radiation Oncology*Biology*Physics with publication year 2024, excluding retracted works and paratext such as editorials and errata. The top 100 by citation count are listed; the percentile is the rank divided by the cohort size. 37 of the 100 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.